labor%20pain
LABOR PAIN
Labor pain experience is highly individualized and will depend on a woman's emotional, motivational, cognitive, cultural and social circumstances.
There is no other circumstance where it is considered acceptable for a patient to experience severe pain that is amenable to safe intervention while under a physician's care.
The pain felt during the 1st stage of labor originates from the rhythmic contractions of the lower uterine segment and progressive cervical dilation mediated via T10-L1 spinal nerves.
The pain in the 2nd stage of labor is more intense due to stretching of the vagina, vulva and perineum as the fetus descends in the birth canal superimposed by the pain of uterine contractions, and is transmitted through the S2-S4 spinal segments.

Labor Pain Drug Information

Drug Information

Indication: Symptomatic relief of moderate to severe pain, especially associated w/ neoplastic disease, MI & surgery. ...

Indication: Management of chronic pain & intractable pain in patients requiring continuous opioid administration for a...

Indication: Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain.

Indication: Local anesth of mucous membrane.

Indication: Surface anaesth of skin during needle insertion, superficial surgical procedures; leg ulcers prior to cleaning...

Indication: Most major nerve blocks eg, sciatic & retrobulbar.

Indication: Surgical anaesth: Epidural block for surgery & field block (minor & major nerve blocks & infiltrat...

Marcain 0.5% Spinal Heavy
bupivacaine hydrochloride + dextrose

Indication: Spinal anaesth for surgery eg, urological surgery & lower limb surgery lasting 2-3 hr & abdominal surg...

1  /  5
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 12 Jan 2021
Adding the CDK4/6 inhibitor abemaciclib to an endocrine therapy of fulvestrant extends overall survival (OS) compared with fulvestrant alone in East Asian patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who have progressed on prior endocrine therapy, consistent with results from the overall population, updated analysis of the global, phase III MONARCH 2 study has shown.